Overview

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib